Masanori Suzuki
| Faculty of Pharmaceutical Sciences,Department of Pharmaceutical Sciences | Lecturer |
Last Updated :2025/10/07
■Researcher basic information
■Career
Career
Member History
■Research activity information
Paper
- Relationship between frailty and Use of Potentially Inappropriate Medications in Elder hospitalized patients：A Cross-Sectional Study
YUKAKO MORISAKI; AYAKO MAEDA‐MINAMI; MASAKI SATO; SAYAKA IZUMI; MASANORI SUZUKI; RYOHKAN FUNAKOSHI; YASUNARI MANO
Sep. 2025, [Reviewed] - Extravascular leakage of dexrazoxane that occurred in a patient with diffuse large B-cell lymphoma: a case report
Nao Wakamiya; Masanori Suzuki; Tatsuya Isezaki; Ryohkan Funakoshi
Journal of Pharmaceutical Health Care and Sciences, 12 Jun. 2025, [Reviewed]
Abstract
Background
Dexrazoxane is used to treat extravascular leakage of anthracycline antitumor agents, but its own extravascular leakage and management remain underreported. This case aimed to highlight both doxorubicin and dexrazoxane leakage during treatment for diffuse large B-cell lymphoma.
Case presentation
A 55-year-old man with diffuse large B-cell lymphoma developed doxorubicin leakage during rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone (R-CHOP) therapy, which was treated with dexrazoxane. Subsequently, dexrazoxane leakage occurred, causing erythema and swelling. Topical clobetasol propionate was applied, leading to symptom resolution without necrosis. The patient successfully completed chemotherapy and achieved long-term remission.
Conclusions
This case report is one of the first to document the management of dexrazoxane extravascular leakage using topical steroids, effectively preventing severe outcomes. The findings suggest that topical steroids may be a desirable treatment approach for dexrazoxane leakage. Prompt intervention and interdisciplinary care contributed to the favorable outcome. This case highlights the need for further research and guideline refinement to optimize the management of inflammatory extravascular leakage. - Relationship Between Frailty and Drug Burden Index in Older Hospitalized Patients
YUKAKO MORISAKI; MISUZU TAKASHIMA; AYAKO MAEDA-MINAMI; SAYAKA IZUMI; MASANORI SUZUKI; RYOHKAN FUNAKOSHI; YASUNARI MANO
In Vivo, 28 Apr. 2025, [Reviewed] - Exploring factors associated with bleeding events after open heart surgery in patients on dialysis − effects of the presence or absence of warfarin therapy
Masanori Suzuki; Yuki Hasegawa; Hiroaki Tanabe; Masayoshi Koinuma; Ryohkan Funakoshi
Journal of Pharmaceutical Health Care and Sciences, 12 Jul. 2024, [Reviewed]
Abstract
Background
Perioperative management of patients on dialysis is critical for controlling bleeding and thrombotic risk, in addition to infection control. Postoperative anticoagulation is often difficult to control, and different institutions have different policies. Therefore, in this study, we aimed to investigate factors associated with postoperative bleeding events and whether warfarin (WF) therapy affects the incidence of postoperative bleeding events, total mortality, and stroke.
Methods
Patients who were admitted to the cardiovascular surgery department and underwent valve replacement or plasty were included, and those who underwent mechanical valve introduction were excluded. Thirty-nine patients were included in the study. The primary endpoint was to identify factors associated with the composite endpoint of postoperative bleeding events, and the secondary endpoint was to determine the effect size of WF therapy on postoperative bleeding events, all-cause mortality, and stroke and the strength of association between the crossed endpoints. The strength of the association between the crossed items was examined.
Results
Low body weight (p = 0.038) was identified as a factor associated with the primary endpoint of postoperative bleeding events. The secondary endpoint of whether or not patients received WF therapy was largely unrelated to bleeding events, all-cause mortality, and postoperative stroke up to 90 days after surgery.
Conclusions
Preliminary studies suggest that low body weight is a risk factor for postoperative bleeding events in patients on dialysis, although further exploration of other factors will be necessary with the accumulation of similar cases. - A Case of Infective Endocarditis with Suspected Vestibular Disorder Caused by Gentamicin Sulfate and Furosemide
秋山眞太郎; 鈴木正論; 鈴木正論; 田邉大明; 舟越亮寛
日本病院薬剤師会雑誌, Oct. 2023, [Reviewed] - 非弁膜性心房細動患者を対象とした直接作用型経口抗凝固薬の服薬アドヒアランスの多施設共同大規模実態調査
Mar. 2021, [Reviewed] - Chorea-like symptoms and high blood concentration of ceftriaxone in a patient undergoing hemodialysis: A case report
Yoshiaki Yokoyama; Naoto Hosokawa; Toshiyuki Kudo; Hitomi Goda; Kiyomi Ito; Masanori Suzuki; Ryohkan Funakoshi
Journal of Infection and Chemotherapy, 2020, [Reviewed] - The Safety Using Ritodrine for Long-Term Tocolysis -The Effects of the Provision of Drug Information by Pharmacists-
末光愛加; 鈴木正論; 鈴木真; 舟越亮寛
医薬品情報学, 2019, [Reviewed] - 腎移植患者における周術期のタクロリムス血中濃度推移の検討
May 2018 - Pharmacist-led intervention in the multidisciplinary team approach optimizes heart failure medication
Masanori Suzuki; Yuya Matsue; Sayaka, Izumi; Ayako Kimura; Tomoaki Hashimoto; Kentaro Otomo; Hiroshi Saito; Makoto Suzuki; Yasuhisa Kato; Ryohkan Funakoshi
Heart and Vessels, 2018, [Reviewed]
We evaluated the impact of pharmacist-led heart failure (HF) drug recommendations during hospitalization for hospitalized patients with HF. Hospitalized patients with HF were retrospectively reviewed. Patients were hospitalized before (n = 208, non-intervention group) or after (n = 170, intervention group) the launch of the HF multidisciplinary team (HFMDT) approach with pharmacist-led HF medication optimization. There were no significant group differences in patient background characteristics at admission. Patients with HF with reduced ejection fraction who were not on beta blockers or angiotensin-converting enzyme inhibitor/angiotensin receptor blockers (ACE-I/ARB) at admission were significantly more likely to be on beta blockers at the time of discharge in the intervention group (73.3 vs 96.3%, P = 0.027) compared to those in non-intervention group; however, the change in ACE-I/ARB prescriptions was not significant (53.3 vs 63.3%, P = 0.601). The proportion of patients on any drug with recommendations against its use in patients with HF did not change from admission to discharge in the non-intervention group (21.2 vs. 20.2%, P = 0.855), but was significantly reduced in the intervention group (22.9 vs. 12.9%, P = 0.005). There were no group differences in the in-hospital all-cause mortality (non-intervention, 3.4%; intervention, 2.4%; P = 0.761) or length of hospital stay (median: non-intervention, 13 days; intervention, 14 days; P = 0.508). Pharmacist-led HF drug recommendations during hospitalization as part of a HFMDT approach for hospitalized patients with HF can increase beta blocker prescriptions and decrease non-preferred drug prescriptions. - Pharmacist Educational Intervention in Intravenous Patient-Controlled Analgesia is Associated with Decreased Postoperative Pain
Ikkou Hirata; Masateru Ito; Eri Hoshino; Masanori Suzuki; Mariko Kawana; Hirokazu Ishizuka; Junko Nagai; Hiromi Yoshinuma; Ryuichi Sekine; Ryohkan Funakoshi
Journal of Hospital and Clinical Pharmacy, Oct. 2016, [Reviewed] - 細菌性髄膜炎患者におけるバンコマイシン薬物動態パラメータの検討(第2報)
May 2016 - 呼吸器内科NST発足後の介入状況の調査
Jan. 2016 - 誤嚥性肺炎の発症状況から見た当院におけるNST薬剤師の役割の検討
Jan. 2016 - A laboratory data-based evaluation of the efficacy and safety of generic pravastatin sodium for long-term use
Masanori Suzuki; Motoyasu Kanamori; Tomoaki Hashimoto; Yuji Hashimoto; Ryohkan Funakoshi; Tadanori Sasaki
Journal of Pharmaceutical Health Care and Science, 2016, [Reviewed]
BACKGROUND: Increasing the use of generic drugs may reduce the growing healthcare spending. Nevertheless, in Japan, the generic drug market share remains low compared to that of European countries and the United States, mainly because of the general distrust of generic drugs. To address this problem, we retrospectively evaluated the efficacy and safety of the long-term use of generic pravastatin sodium in a study from January 2008 to December 2011. METHODS: Patients receiving generic pravastatin sodium for ≥15 months were defined as long-term users and were included in the study, totaling 595 out of 1337 patients. Efficacy assessment was based on the total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) plasma levels. Safety assessment was based on the aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine phosphokinase (CPK), gamma-glutamyl transferase (γ-GTP), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total-bilirubin (T-Bil), blood urea nitrogen (BUN), serum creatinine (Scr), and hemoglobin A1c (HbA1c) plasma levels. The patients' reasons for discontinuing generic pravastatin sodium were obtained from the electronic medical records. RESULTS & DISCUSSION: No significant difference in the laboratory data was observed between short-term and long-term users, except for significantly lower ALT levels in the long-term users than in the short-term users. No liver dysfunction was observed. Although 37 patients discontinued the study possibly owing to drug-related adverse events, we considered these events unrelated to generic pravastatin sodium. CONCLUSIONS: This study shows that the long-term use of generic pravastatin sodium is effective and safe, and may help dispel the concerns about generic drugs. - 細菌性髄膜炎患者におけるバンコマイシンのクリアランスの検討
May 2015 - 薬剤師による医薬品適正使用情報提供が薬物治療に及ぼす影響-アリスキレンとACE阻害薬またはARBの併用について-
2013, [Reviewed] - プラバスタチンNa錠の後発医薬品への切り替えに伴う臨床検査値に基づく臨床効果の評価および安全性評価
Aug. 2011, [Reviewed] - Induction of pulmonary fibrosis by methotrexate treatment in mice lung in vivo and in vitro
Masayuki Ohbayashi; Masanori Suzuki; Yoshiki Yashiro; Sayaka Fukuwaka; Masako Yasuda; Noriko Kohyama; Yasuna Kobayashi; Toshinori Yamamoto
The Journal of Toxicological Sciences, 2010, [Reviewed]
Methotrexate (MTX) has been used as the first-line disease-modifying antirheumatic drug (DMARD) in patients with early progressive rheumatoid arthritis (RA). Several severe side effects such as myelosuppression, hepato-, nephro-, and pulmonary toxicities have been reported. However, the pathogenic mechanism of MTX-induced pulmonary fibrosis is still unknown. Here, we evaluated the morphological and biological changes of the pulmonary fibrosis in mice treated with MTX. Three, four and five weeks after consecutive administration of MTX (3 mg/kg/day), hydroxyproline content in the lung tissues increased significantly to about 2 times higher that of the control level. This result closely reflected to the results of hematoxylin and eosin (HE) and Azan stains. Immunohistochemical analysis revealed that MTX treatment resulted in a decrease of alveolar epithelial cells and an increase of fibroblast cells in the mouse lung tissues. When we examined the effects of MTX on primary mouse alveolar epithelial cell (MAEC) and mouse lung fibroblast (MLF) survival in vitro, the efficiency of MTX-induced cytotoxicity and apoptosis in MAEC was more sensitive than MLF cells. Thus, our results indicate that the administration of MTX by an oral route could induce a fibrotic response with cell dysfunction of the alveolar epithelium by which MTX-induced apoptosis. Our results thus suggest that MTX could induce alveolar epithelial cell injury and resulted in the loss of integrity of the alveolar-capillary barrier basement membranes followed by the recruitment and proliferation of myofibroblasts with the deposition of collagens. - カルボプラチン点滴静注液「サンド」使用成績調査における臨床検査値を用いた安全性に関する評価
2009, [Reviewed]
MISC
- 精神科病棟における病棟薬剤師の役割
高橋 治樹; 鈴木 正論; 安室 修; 永井 淳子; 船越 亮寛; 小石川 比良来; 佐々木 忠徳
総合病院精神医学, Jan. 2016
(一社)日本総合病院精神医学会 - 進行卵巣癌に対してパクリタキセル・カルボプラチン併用療法を行った透析患者の1例 血液透析によるカルボプラチンの除去率の検討
荘司 希奈; 松浦 拓人; 桝田 浩司; 鈴木 正論; 永井 淳子; 大塚 伊佐夫; 佐々木 忠徳
日本薬学会年会要旨集, Mar. 2014
(公社)日本薬学会 - 薬剤管理指導業務における介入事例の分析
大西 潤; 鈴木 正論; 田中 仁; 石橋 正祥; 秋葉 久典; 永井 淳子; 佐々木 忠徳
日本薬学会年会要旨集, Mar. 2011
(公社)日本薬学会 - カルボプラチン点滴静注剤「サンド」使用成績調査における臨床検査値を用いた安全性に関する評価
佐々木 忠徳; 竹本 伸輔; 黄前 尚樹; 白澤 吉哲; 大西 潤; 鈴木 正論; 橋本 裕子; 鰐口 和也; 林 淳雄; 佐原 敏之; 北澤 勉
臨床薬理, Nov. 2008
(一社)日本臨床薬理学会 - MTX誘発間質性肺炎モデルマウスの作製
鈴木 正論; 大林 真幸; 保田 晶子; 神山 紀子; 小林 靖奈; 山元 俊憲
日本薬学会年会要旨集, Mar. 2006
(公社)日本薬学会 - 癌性疼痛におけるモルヒネ使用上の副作用対策~大学院病棟実習を通して~
鈴木正論; 岩切麻里子; 阿部誠治; 柏原由佳; 大林真幸; 金山朱里; 野瀬清; 村山純一郎; 山元俊憲
日本医療薬学会年会講演要旨集, 01 Sep. 2005
Books and other publications
- 循環ドリル第8回心不全と頻脈性不整脈（心房細動）の蜜月な関係とは？-心房細動と心不全が相互に及ぼす影響を考察してみよう！
Contributor
2021 - 慢性心不全患者の薬物動態，「ニガテさん」のための薬物動態
Contributor
2021 - リハに役立つ治療薬の知識とリスク管理
Contributor
2019 - β遮断薬, 慢性心不全スタートブック
Contributor
2019 - それって本当に副作用ですか？この「咳」は降圧薬によるものですか？
Contributor
2019 - 専門薬剤師リレーエッセイ，一歩ずつ
2018 - 循環器疾患 薬の解説，わかりやすい疾患と処方薬の解説2013年改訂版-病態・薬物治療編-
Contributor
2013 - チーム医療における各職種の役割⑥薬剤師，チームで取り組む心臓デバイス植え込み患者のケアとマネジメント
Contributor
2012 - がっちりマスター！クスリナビ「心不全患者さんのクスリ」
Contributor
2011
Lectures, oral presentations, etc.
- ハートチームで薬剤師に求められるもの
17 Jan. 2022, [Invited] - シンポジウム20「周術期における抗血栓療法～どの時点で、何を評価し、どう対応する？」
[Invited] - 薬物療法専門薬剤師ワークショップ1「ジェネラリストとしての薬剤師力を磨く(2)～実践！複合疾患を有する患者への薬学的アプローチ」
24 Oct. 2020, [Invited] - 薬物療法専門薬剤師ワークショップ「ジェネラリストとしての薬剤師力を磨く～実践！複合疾患を有する患者への薬学的アプローチ」
02 Nov. 2019, [Invited] - 心臓に「良い薬」と「悪い薬」を考える〜心不全チーム医療における薬剤師の役割〜
24 Oct. 2019, [Invited] - 臨床薬剤師業務をいかにアウトプットするか-循環器多職種協働事例より-
24 Jun. 2018, [Invited] - Warfarin pharmacotherapy protocol-based pharmacist-led management for cardiac surgery patients
Masanori Suzuki; Sayaka Izumi; Yui Tanimoto; Hiroaki Tanabe; Ryohkan Funakoshi
78th FIP Congress (Glasgow), 2018 - 腎移植における免疫抑制療法と薬剤師の関わり
09 Jul. 2017, [Invited] - Protocol-based management of warfarin pharmacotherapy by pharmacists in perioperative cardiac surgery patients
Masanori Suzuki; Sayaka Izumi; Yui Tanimoto; Hidehito Takano; Osamu Yasumuro; Taiki Kawaida; Yoichiro Machida; Mitsuhisa Kotani; Mikio Sasano; Yoshiro Hayashi; Hiroaki Tanabe; Ryohkan Funakoshi
European Society of Cardiology Acute Cardiovascular Care (Lisbon), Oct. 2016 - 当院における適正な抗凝固療法への取り組み
26 Aug. 2016, [Invited] - Pharmacotherapy intervention by pharmacist in multidisciplinary team for heart failure
Masanori Suzuki; Yuya Matsue; Sayaka Izumi; Tomoaki Hashimoto; Kentaro Otomo; Junko Nagai; Ryokan Funakoshi; Makoto Suzuki; Yuji Hashimoto; Tadanori Sasaki
75th FIP Congress (Dusseldorf), Sep. 2015 - 心不全チームへの薬剤師参画の効果
21 Feb. 2015, [Invited] - 心不全回診における薬剤師主導の薬物治療適正化
01 Jul. 2014, [Invited] - 薬剤師の立場から
05 Jun. 2014, [Invited] - An evaluation of efficacy and safety of long-term use of generic pravastatin sodium in hyperlipidemia
Masanori Suzuki; Motoyasu Kanamori; Tomoaki Hashiomoto; Tadanori Sasaki
25th FAPA Congress (Malaysia), 2014 - 心不全多職種チームにおける薬剤師主導介入による薬物治療適正化
Nov. 2013 - 病棟薬剤業務の開始前後における薬剤師によるアウトカム調査
Sep. 2013 - プロフェッショナルとしての薬剤師の育成とその評価系を目指して
01 Feb. 2013, [Invited] - 病棟薬剤業務を実践するための戦略～果たすべき役割とその成果～
01 Feb. 2013, [Invited] - 病棟薬剤師の業務について
06 Nov. 2012, [Invited] - 病棟薬剤業務を実践するための戦略～果たすべき役割とその成果～
02 Nov. 2012, [Invited] - 薬物治療の標準化推進の意義と薬剤師の使命
22 Apr. 2012, [Invited] - プラバスタチンNa錠の後発医薬品への切り替えに伴う有効性・安全性評価 -第2報-
Oct. 2011 - TPN鑑査チェックリスト運用前後における栄養状態関連臨床検査値の変化
Feb. 2011 - SLE 患者における血漿交換療法施行中の塩酸バンコマイシンTDM実施症例
Aug. 2010 - プラバスタチンNa錠の後発医薬品への切り替えに伴う有効性・安全性評価-第1報-
Oct. 2009 - 後発医薬品を導入する際の看護師業務における問題点の抽出とその対策
Sep. 2008 - 後発医薬品を導入する際の看護師業務における問題点の抽出とその対策
Sep. 2007 - MTX誘発間質性肺炎モデルマウスの作製
Mar. 2006 - 癌性疼痛におけるモルヒネ使用上の副作用対策－大学院病棟実習を通して－
Oct. 2005
Affiliated academic society
